No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
APLT Applied Therapeutics
- 4.230
- -0.080-1.86%
Close Apr 25 16:00 ET
- 4.250
- +0.020+0.47%
Post 19:20 ET
483.24MMarket Cap-2978P/E (TTM)
4.360High4.170Low568.73KVolume4.200Open4.310Pre Close2.42MTurnover0.62%Turnover RatioLossP/E (Static)114.24MShares9.39052wk High-28.20P/B387.45MFloat Cap1.18052wk Low--Dividend TTM91.60MShs Float57.390Historical High--Div YieldTTM4.41%Amplitude0.500Historical Low4.250Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Applied Therapeutics Welcomes Dale Hooks as New CCO
Express News | Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
RBC Capital Sticks to Their Buy Rating for Applied Therapeutics (APLT)
Express News | RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
CNDT, CHRS and OM Are Among Materials Movers
Express News | Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024
Comments
See what comes from this? Along with my post from 3/28! LIKE!
$Applied Therapeutics(APLT.US$ Applied Therapeutics Plans To Present Results From Phase 3 ARISE-HF Study In Diabetic Cardiomyopathy At ACC 2024
1
Make a note!
$Applied Therapeutics(APLT.US$ Applied Therapeutics said regulators had extended the period for reviewing its application for a rare metabolic disease treatment.
The biopharmaceutical company said Thursday that the Food and Drug Administration now has a target action date of Nov. 28 for its application, compared with the previous date of Aug. 28.
The company's application is for govorestat in the treatment of Galactosemia, a rare genetic condition that makes patients unable to metab...
The biopharmaceutical company said Thursday that the Food and Drug Administration now has a target action date of Nov. 28 for its application, compared with the previous date of Aug. 28.
The company's application is for govorestat in the treatment of Galactosemia, a rare genetic condition that makes patients unable to metab...
Therapeutics Company Announce FDA Acceptance For New Galactosemia Treatment
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia: A Revolution in Healthcare.
In a significant development for the healthcare sector and investors worldwide, Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company, has announced the Food and Drug Administration's acceptance and priority review of t...
In a significant development for the healthcare sector and investors worldwide, Applied Therapeutics Inc. (NASDAQ:APLT), a clinical-stage biopharmaceutical company, has announced the Food and Drug Administration's acceptance and priority review of t...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg